Roth Capital Issues Negative Forecast for Cryoport Earnings

Cryoport, Inc. (NASDAQ:CYRX - Free Report) - Roth Capital decreased their Q1 2025 earnings estimates for shares of Cryoport in a report issued on Wednesday, March 5th. Roth Capital analyst R. Baldry now forecasts that the company will earn ($0.34) per share for the quarter, down from their prior estimate of ($0.32). The consensus estimate for Cryoport's current full-year earnings is ($0.99) per share. Roth Capital also issued estimates for Cryoport's Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.33) EPS, Q4 2025 earnings at ($0.31) EPS, FY2025 earnings at ($1.30) EPS, Q1 2026 earnings at ($0.32) EPS, Q2 2026 earnings at ($0.31) EPS, Q3 2026 earnings at ($0.31) EPS and Q4 2026 earnings at ($0.29) EPS.

CYRX has been the subject of several other research reports. Guggenheim assumed coverage on shares of Cryoport in a report on Thursday, December 19th. They issued a "buy" rating and a $11.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $11.00 target price on shares of Cryoport in a report on Wednesday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat, Cryoport currently has a consensus rating of "Moderate Buy" and a consensus price target of $12.29.

Cryoport Stock Down 6.5 %

Shares of Cryoport stock traded down $0.43 during trading hours on Friday, hitting $6.23. The company had a trading volume of 386,284 shares, compared to its average volume of 315,400. The company's 50-day moving average is $7.25 and its two-hundred day moving average is $7.58. Cryoport has a twelve month low of $4.58 and a twelve month high of $20.10. The company has a debt-to-equity ratio of 0.48, a current ratio of 5.70 and a quick ratio of 5.32. The company has a market cap of $307.96 million, a P/E ratio of -1.84 and a beta of 1.67.

Remove Ads

Cryoport (NASDAQ:CYRX - Get Free Report) last announced its quarterly earnings data on Tuesday, March 4th. The company reported ($0.42) EPS for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.09). Cryoport had a negative net margin of 70.08% and a negative return on equity of 13.35%. The firm had revenue of $59.53 million during the quarter, compared to analysts' expectations of $58.71 million. During the same period in the prior year, the company posted ($0.29) earnings per share.

Hedge Funds Weigh In On Cryoport

Large investors have recently made changes to their positions in the stock. Point72 Asia Singapore Pte. Ltd. increased its holdings in shares of Cryoport by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC acquired a new position in Cryoport during the fourth quarter worth about $51,000. Avanza Fonder AB acquired a new position in Cryoport during the fourth quarter worth about $64,000. Quarry LP acquired a new position in Cryoport during the fourth quarter worth about $69,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Cryoport during the third quarter worth about $82,000. Hedge funds and other institutional investors own 92.90% of the company's stock.

Cryoport Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.